Clazakizumab is an investigational humanized anti-interleukin-6 monoclonal antibody previously developed by Bristol Myers Squibb and Alder Biopharmaceuticals. It has been studied in inflammatory disease settings including psoriatic arthritis. The drug remains investigational and not approved as a marketed product.
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.
CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly outside of ESKD-related cardiovascular risk. CSL receives $100 million upfront and retains rights to the ESKD indication.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05727384 |
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04494724 |
Clazakizumab vs. Placebo - COVID-19 Infection |
UNKNOWN | PHASE2 |
| NCT04381052 |
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection |
TERMINATED | PHASE2 |
| NCT04348500 |
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19) |
COMPLETED | PHASE2 |
| NCT04129931 |
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study |
COMPLETED | PHASE2 |
| NCT03744910 |
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients |
TERMINATED | PHASE3 |
| NCT03380962 |
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03380377 |
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant |
COMPLETED | PHASE1/PHASE2 |
| NCT02015520 |
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis |
COMPLETED | PHASE2 |
